PharmaFocus Today – Page 120 – media

Uganda launches vaccine trial for Sudan Ebola virus

Kampala, February 4: Uganda’s Ministry of Health, the World Health Organization and other partners launched the world’s first vaccine trial for Sudan Ebola virus on February 3 local time. On January 30 local time, the Ugandan Ministry of Health announced that the country had an Ebola outbreak again after a lapse of two years, and a nurse in the capital Kampala died of Ebola virus infection. A statement issued by the WHO said that after the outbreak, Uganda’s local leading researchers prepared for the trial within 4 days with the support of the WHO and other partners. This is the first clinical efficacy trial of a vaccine against Sudan Ebola virus. Reuters reported that the trial will mainly target contacts of confirmed cases. According to the Associated Press, on February 3, two more relatives of the deceased nurse were confirmed to be infected with Ebola virus. The Ugandan government is ...
- Source: drugdu
- 193
- February 6, 2025
Merck will suspend the supply of HPV vaccine Gardasil to the Chinese market

On February 4, local time, Merck announced the suspension of the supply of HPV vaccine Gardasil to China, and the suspension is expected to last at least until the middle of the year. The financial report released by Merck on the same day showed that the company’s fourth quarter sales were US$15.6 billion, a year-on-year increase of 7%, of which Gardasil sales fell 17% year-on-year to US$1.55 billion. Merck said the main reason was the reduction in demand in China. In January this year, Merck’s HPV vaccine Gardasil was approved for marketing by the National Medical Products Administration for multiple new indications, suitable for males aged 9 to 26, becoming the first and currently the only approved HPV vaccine for men in China. https://finance.eastmoney.com/
- Source: drugdu
- 223
- February 6, 2025
mRNA RSV vaccine applied for clinical trials in the United States

Aimi Vaccine’s mRNA vaccine series product research and development has made new progress. The company announced on February 5 that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently applied for clinical trials to the U.S. Food and Drug Administration (FDA). According to the announcement, in preclinical animal trials, the test results of third-party testing units showed that Aimi’s mRNA RSV vaccine specific IgG antibody titer, true virus neutralizing antibody titer, and specific T cell immunity were significantly higher than the internationally listed mRNA RSV control vaccine. As one of the main pathogens causing lower respiratory tract infections in infants and young children, the market demand for its vaccine is also huge. The global sales of RSV vaccines in 2023 were US$2.46 billion. According to the forecast of Zhushi Consulting, the global market size of RSV vaccines is expected to reach approximately US$16.7 billion by 2030. If the ...
- Source: drugdu
- 224
- February 6, 2025
the equity transfer contract has come into effect

On February 4, Chongqing Pharmaceutical Holdings (000950) issued an announcement on the progress of the proposed change in the equity structure of the controlling shareholder. The company disclosed a relevant indicative announcement on January 11, 2025. Chongqing Chemical and Pharmaceutical Holdings (Group) Co., Ltd., a shareholder of the controlling shareholder Chongqing Pharmaceutical and Health Industry Co., Ltd., and Chongqing Yufu Holdings Group Co., Ltd. signed an equity transfer contract, intending to transfer 49% of Chongqing Chemical and Pharmaceutical Holdings to Chongqing Yufu. It is worth noting that the actual controllers of Chongqing Chemical and Pharmaceutical Group and Chongqing Yufu are both the Chongqing State-owned Assets Supervision and Administration Commission. According to the announcement, as of January 27, 2025, the company has received the “Notice Letter” from Chongqing Medical Health, confirming that Chongqing Chemical and Pharmaceutical Group has obtained the approval of the Chongqing State-owned Assets Supervision and Administration Commission, and ...
- Source: drugdu
- 401
- February 5, 2025
Innovative drugs led the gains during the session, and the innovative drug Shanghai-Shenzhen-Hong Kong ETF (517110) rose by more than 1.3%

Innovative drugs led the gains during the session, and the innovative drug Shanghai-Shenzhen-Hong Kong ETF (517110) rose by more than 1.3%. Galaxy Securities said that the pharmaceutical sector has undergone a long period of adjustment, the overall valuation is at a low level, and the public offering positions are underweight. In 2025, under the policy background of supporting and guiding the development of commercial insurance, the payment side is expected to improve marginally, and innovative drugs and equipment are expected to benefit. The pharmaceutical market will usher in a recovery, and structural opportunities still exist. From the perspective of short-term and medium- and long-term deterministic growth, targets are selected, and innovative drugs and industrial chains are optimistic about the continued good performance this year. Investors without stock accounts can seize investment opportunities in innovative drugs through the link fund (014118) of the innovative drug Shanghai-Shenzhen-Hong Kong ETF. Source: https://finance.eastmoney.com/
- Source: drugdu
- 305
- February 5, 2025
Diet pills should be used with caution

Recently, oral semaglutide tablets were approved by the National Medical Products Administration for full marketing in China. This is the first and only oral GLP-1 (glucagon-like peptide-1) drug approved for marketing in China. The reporter learned in the interview that the number of patients who went to the hospital to consult about this oral semaglutide has increased recently, and some of them hope to lose weight with this drug. So what exactly is semaglutide tablets used to treat, and what is its relationship with the weight loss “magic drug” that has been frequently mentioned on social media before? Semaglutide is a class of GLP-1 receptor agonists. Its working principle is to stimulate insulin synthesis and secretion in a glucose concentration-dependent manner after binding to the GLP-1 receptor, and reduce the secretion of glucagon. At the same time, it can also act on the GLP-1 receptors of the central nervous system, ...
- Source: drugdu
- 260
- February 5, 2025
Losses of 900 million to 1.3 billion yuan are expected in 2024

Hainan Haiyao (000566) disclosed its 2024 performance forecast on the evening of January 27, and it is expected to achieve operating income of 1 billion to 1.2 billion yuan in 2024; net profit attributable to the parent company will be a loss of 900 million to 1.3 billion yuan, compared with a loss of 106 million yuan in the same period last year; net profit excluding non-recurring items will be a loss of 700 million to 1 billion yuan, compared with a loss of 410 million yuan in the same period last year; basic earnings per share will be -0.6937 yuan/share to -1.002 yuan/share. Based on the closing price on January 27, Hainan Haiyao’s current price-to-earnings ratio (TTM) is about -4.29 times to -6.2 times, price-to-book ratio (LF) is about 3.16 times, and price-to-sales ratio (TTM) is about 5.07 times. According to the data, the company’s main business is the ...
- Source: drugdu
- 268
- February 5, 2025
Shandong YaoBo’s controlling shareholder released the pledge of 8.48 million shares

On January 27, Shandong YaoBo (600529) issued an announcement that the controlling shareholder Shandong Luzhong Investment released the pledge of 8.48 million shares, accounting for 6.55% of its shares and 1.28% of the company’s total share capital; as of the date of the announcement, Luzhong Investment had pledged a total of 53.8 million shares, accounting for 41.58% of its shares and 8.11% of the company’s total share capital. In the first three quarters of 2024, Shandong YaoBo achieved revenue of 3.825 billion yuan and net profit attributable to the parent of 720 million yuan. Source: https://finance.eastmoney.com/
- Source: drugdu
- 302
- February 5, 2025
Popular weight loss drugs have benefits and risks

In an observational study published in the latest issue of Nature Medicine, scientists analyzed the health effects of using glucagon-like peptide 1 receptor agonists (GLP-1RAs), concluding that 42 health risks decreased and 19 health risks increased. GLP-1RAs have become popular in the past few years because of their claims of weight loss. People are also studying the broader efficacy of GLP-1RAs, including the treatment of diseases such as Alzheimer’s disease, osteoarthritis and sleep apnea. However, some adverse events such as suicidal tendencies and gastrointestinal problems have also been reported. Therefore, it is necessary to further study the health benefits and risks of GLP-1RAs. A team from Washington University in St. Louis analyzed data from the U.S. Department of Veterans Affairs and studied the relationship between the use of GLP-1RAs and 175 health outcomes in 215,970 diabetic patients. Compared with a control group using non-GLP-1RA anti-hyperglycemic drugs, participants using GLP-1RA had ...
- Source: drugdu
- 289
- February 5, 2025
2025 will be a year of overseas expansion | Make a wish in spring

In mid-January 2025, WuXi Biologics announced that the company will add 151 projects in 2024, bringing the total number of projects to 817; the company expects that 24 PPQ (process performance confirmation) projects will be advanced in 2025, and the Irish production facility is expected to achieve profitability as planned in 2025. The above announcement actually conveys two very important messages. In 2024, the number of new projects of WuXi Biologics reached a new high. At the same time, the company’s “pioneer” Irish base in the international layout of that year ushered in a major breakthrough. But behind this announcement, as WuXi Biologics CEO Chen Zhisheng commented, it was a year of “roller coaster” for WuXi Biologics. In the ten years from 2014 to 2023, WuXi Biologics’ revenue compound annual growth rate exceeded 50%, which means that the company achieved a growth rate that was three times higher than the ...
- Source: drugdu
- 445
- February 5, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.